pdf   xlsx method abbreviations

metastatic/advanced - colorectal cancer (mCRC), atezolizumab based treatment versus Standard of Care (SoC), meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.98 [0.64, 1.50]< 10%1 study (1/-)53.7 %NAnot evaluable crucial-
deaths (OS) (extension) 0.83 [0.65, 1.05]< 10%1 study (1/-)93.6 %NAnot evaluable important-
PFS (extension) 0.95 [0.77, 1.18]< 10%1 study (1/-)68.1 %NAnot evaluable important-
progression or deaths (PFS) 0.92 [0.72, 1.17]< 10%1 study (1/-)75.0 %NAnot evaluable important-

safety endpoints 00

AE (any grade) 2.49 [1.25, 4.95]< 10%1 study (1/-)0.5 %NAnot evaluable non important-
AE (grade 3-5) 1.40 [0.91, 2.15]< 10%1 study (1/-)6.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons